Literature DB >> 19232762

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.

Sandeep A Saha1, Rohit R Arora.   

Abstract

OBJECTIVE: Fibrates are thought to be useful anti-dyslipidemic agents particularly in patients with diabetes mellitus and dyslipidemia characterized by high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) levels. We conducted a systematic review and meta-analysis of long-term randomized controlled trials to evaluate the role of fibrates in the prevention of cardiovascular events in patients with type 2 diabetes mellitus. DATA SOURCES: English-language journals indexed in Index Medicus/MEDLINE and the Cochrane Collaboration databases (through December 2007), unpublished data from selected clinical trials. DATA EXTRACTION AND ANALYSIS: A total of 11,590 patients from 6 published randomized placebo-controlled trials were analyzed using pooled meta-analysis techniques. Relative risks were computed for various cardiovascular outcomes and mortality, and statistical significance was tested using the z-test statistic (two-sided alpha error <0.05).
RESULTS: The use of fibrates did not significantly affect the risk of all-cause mortality or cardiac mortality, and also did not affect the risk of stroke, unstable angina, or invasive coronary revascularization. However, the relative risk of non-fatal myocardial infarction was significantly reduced by about 21% (pooled relative risk 0.79, p=0.006) with the use of fibrates.
CONCLUSIONS: Long-term use of fibrates in patients with type 2 diabetes mellitus significantly reduces the risk of non-fatal myocardial infarction, but has no significant effect on mortality or on other adverse cardiovascular outcomes. Copyright 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232762     DOI: 10.1016/j.ijcard.2008.11.211

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  Epidemiology and prevention of stroke: a worldwide perspective.

Authors:  Elena V Kuklina; Xin Tong; Mary G George; Pooja Bansil
Journal:  Expert Rev Neurother       Date:  2012-02       Impact factor: 4.618

2.  Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARα-regulated β-oxidative enzymes.

Authors:  Anca D Petrescu; Huan Huang; Gregory G Martin; Avery L McIntosh; Stephen M Storey; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-12-13       Impact factor: 4.052

3.  High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes.

Authors:  Anca D Petrescu; Avery L McIntosh; Stephen M Storey; Huan Huang; Gregory G Martin; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  Biochim Biophys Acta       Date:  2013-06-06

4.  The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.

Authors:  Gregory G Martin; Avery L McIntosh; Huan Huang; Shipra Gupta; Barbara P Atshaves; Kerstin K Landrock; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  Biochemistry       Date:  2013-12-10       Impact factor: 3.162

Review 5.  Combination therapy of statins and fibrates in the management of cardiovascular risk.

Authors:  Catherine Fiévet; Bart Staels
Journal:  Curr Opin Lipidol       Date:  2009-12       Impact factor: 4.776

Review 6.  Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias.

Authors:  Friedhelm Schroeder; Avery L McIntosh; Gregory G Martin; Huan Huang; Danilo Landrock; Sarah Chung; Kerstin K Landrock; Lawrence J Dangott; Shengrong Li; Martin Kaczocha; Eric J Murphy; Barbara P Atshaves; Ann B Kier
Journal:  Lipids       Date:  2016-04-27       Impact factor: 1.880

Review 7.  Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.

Authors:  Stefanos Bonovas; Georgios K Nikolopoulos; Pantelis G Bagos
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 8.  The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

Authors:  Charikleia Kalliora; Konstantinos Drosatos
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

Review 9.  Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment.

Authors:  Victoria A Serhiyenko; Alexandr A Serhiyenko
Journal:  World J Diabetes       Date:  2018-01-15

10.  Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data.

Authors:  Sabita S Soedamah-Muthu; Johanna M Geleijnse; Erik J Giltay; Daan Kromhout
Journal:  BMJ Open       Date:  2012-10-31       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.